A study of depressed individuals found that an eight‐week treatment with selective serotonin reuptake inhibitors (SSRIs) reduced the activity of 5-HT4 receptors—a specific type of serotonin ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Wearables could soon help detect changes in your mood, helping spot symptoms of depression and offering solutions.

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Australians will wait an average of 12 years before getting treatment for mental health or substance use disorders, according ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

A two-part clinical trial led by University of Cincinnati researchers at the Lindner Center of HOPE is testing the use of ...